Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus METUBINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus METUBINE IODIDE.
FEXINIDAZOLE vs METUBINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Nondepolarizing neuromuscular blocking agent; competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing depolarization and muscle contraction.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
0.1-0.3 mg/kg IV as a single dose for neuromuscular blockade during surgery. Additional doses of 0.03-0.05 mg/kg at 25-30 minute intervals as needed.
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life: approximately 2-3 minutes (due to rapid redistribution from plasma to tissues), with a longer terminal phase (30-60 minutes) reflecting slow efflux from deep compartments.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Primarily renal excretion of unchanged drug (approximately 70-80% over 24 hours); biliary/fecal excretion accounts for <10%.
Category C
Category C
Antiprotozoal
Antiprotozoal